Rolf L. Larsson
Impact in
- Oncology top 1%
- Peptidase Inhibition and Analysis
- Hematology top 1%
Papers in
- Oncology 88
- Peptidase Inhibition and Analysis 18
- Drug Transport and Resistance Mechanisms 17
-
- Cancer therapeutics and mechanisms 26
- Metabolism, Diabetes, and Cancer 15
- Co-authors
- Peter Nygren (142 shared papers)Joachim Gullbo (44 shared papers)Mårten Fryknäs (57 shared papers)Bo Nilsson (17 shared papers)Malin Wickström (18 shared papers)Graciela Elgue (13 shared papers)Olle Korsgren (6 shared papers)Stig T. Linder (19 shared papers)
- Journals
- Anti-Cancer Drugs (18 papers)International Journal of Cancer (12 papers)Biochemical Pharmacology (11 papers)Oncotarget (7 papers)Cancer Chemotherapy and Pharmacology (6 papers)
- Partner nations
- SwedenUnited StatesDenmark
In The Last Decade
Rolf L. Larsson
306 papers receiving 11.1k citations
Peers
Comparison fields: 5 of 153
- Oncology 2.4k
- Hematology 973
- Cancer Research 1.1k
- Molecular Biology 5.2k
- Geriatrics and Gerontology 187
Countries citing papers authored by Rolf L. Larsson
This map shows the geographic impact of Rolf L. Larsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf L. Larsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf L. Larsson more than expected).
Fields of papers citing papers by Rolf L. Larsson
This network shows the impact of papers produced by Rolf L. Larsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf L. Larsson. The network helps show where Rolf L. Larsson may publish in the future.
Co-authors
The 25 scholars most cited alongside Rolf L. Larsson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 307 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 437 | |
| 2 | 2010 | 317 | |
| 3 | 2013 | 299 | |
| 4 | 2000 | 295 | |
| 5 | Cyclotides: a novel type of cytotoxic agents. | 2002 | 245 |
| 6 | 2002 | 232 | |
| 7 | 2014 | 210 | |
| 8 | 1992 | 208 | |
| 9 | 2008 | 201 | |
| 10 | 2016 | 183 | |
| 11 | 2000 | 181 | |
| 12 | 2003 | 167 | |
| 13 | 2009 | 165 | |
| 14 | 1999 | 163 | |
| 15 | 2012 | 157 | |
| 16 | 2002 | 132 | |
| 17 | 2015 | 125 | |
| 18 | Alpha terpineol: a potential anticancer agent which acts through suppressing NF-kappaB signalling. | 2010 | 122 |
| 19 | 1998 | 118 | |
| 20 | Translocation and enhancement of phosphotransferase activity of protein kinase C following exposure in mouse epidermal cells to oxidants. | 1989 | 117 |
About Rolf L. Larsson
Rolf L. Larsson is a scholar working on Oncology, Molecular Biology, Hematology, Cancer Research and Nephrology, having authored 307 papers that have together received 11.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (26 papers), Acute Lymphoblastic Leukemia research (22 papers), Cancer, Hypoxia, and Metabolism (18 papers), Peptidase Inhibition and Analysis (18 papers), Acute Myeloid Leukemia Research (18 papers), Drug Transport and Resistance Mechanisms (17 papers), Parathyroid Disorders and Treatments (17 papers) and Metabolism, Diabetes, and Cancer (15 papers). The work is most often cited by research in Oncology (2.4k citations), Hematology (973 citations), Cancer Research (1.1k citations), Molecular Biology (5.2k citations) and Geriatrics and Gerontology (187 citations). Rolf L. Larsson has collaborated with scholars based in Sweden, United States and Denmark. Frequent co-authors include Peter Nygren, Joachim Gullbo, Mårten Fryknäs, Bo Nilsson, Malin Wickström, Graciela Elgue, Olle Korsgren, Stig T. Linder, Linda Rickardson and Kristina Nilsson Ekdahl. Their work appears in journals such as Anti-Cancer Drugs, International Journal of Cancer, Biochemical Pharmacology, Oncotarget and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.